Obesity (adiposity): causes, weight-loss injection & treatment

At a glance

Affected in Germany ~13 million adults (approx. 19 %); approx. 6 % of children/adolescents
Definition Usually a BMI ≥ 30 kg/m² — grade I (30–34.9), grade II (35–39.9), grade III (≥ 40)
Other names Adiposity, severe overweight
Secondary diseases e.g. type 2 diabetes, heart attack, stroke, sleep apnoea, cancer, osteoarthritis
Medications (selection) Semaglutide (Wegovy), tirzepatide (Mounjaro/Zepbound), orlistat
ICD-10 E66

1. What is obesity?

Obesity (adiposity, severe overweight) is a chronic disease — not a weakness of will and not a free choice. It usually arises through a complex interplay of genetics, hormones, mental health, environment and lifestyle. The German Bundestag (parliament) officially recognized obesity as a disease in 2020.

In Germany, according to RKI (Robert Koch Institute) data, around 13 million adults are affected — about one in five.¹ The prevalence has increased over the past decades, especially in younger age groups and in education groups with a lower socioeconomic status.

Even a 5–10 % weight loss helps markedly Even a weight loss of about 5–10 % of body weight can markedly improve blood sugar, blood pressure and blood lipids.² With modern medications (semaglutide, tirzepatide), average weight losses of about 10–20 % have been described in studies.⁴˒⁵

2. BMI, waist circumference and new diagnostic criteria (Lancet 2025)

BMI classification (WHO)

CategoryBMI (kg/m²)Meaning
Normal weight18.5–24.9No increased weight risk
Overweight (pre-obesity)25.0–29.9Increased risk, not yet a disease
Obesity grade I30.0–34.9Markedly increased risk
Obesity grade II35.0–39.9Strongly increased risk
Obesity grade III (morbid)≥ 40.0Very strongly increased risk
Table scrollable to the right

Waist circumference — often more meaningful than BMI alone

BMI does not capture where the fat is located. Visceral abdominal fat in particular (around the internal organs) is regarded as a risk factor for metabolic and cardiovascular diseases.

Waist circumference risk thresholds (orientation values per WHO/IDF) Women: > 88 cm → increased cardiometabolic risk — even with a normal BMI.
Men: > 102 cm → increased cardiometabolic risk — even with a normal BMI.

Lancet Commission 2025: a new diagnostic logic

An international expert commission (Lancet Diabetes & Endocrinology, January 2025), supported by more than 75 international professional societies, recommends a fundamental reassessment: BMI alone is often not enough. In addition, waist circumference, direct fat measurement and organ function should be taken into account.

  • Clinical obesity: excess body fat has already led to chronic organ damage (e.g. diabetes, heart failure, sleep apnoea, osteoarthritis). According to the commission, prompt, intensive therapy is indicated.³
  • Preclinical obesity: increased body fat without detectable organ damage. An increased-risk state, but not yet a disease in the narrower sense. Preventive strategies are the priority.
A note on the Lancet Commission The new categorization is partly disputed among experts — some professional societies criticize that the subdivision could delay access to therapies. Regardless of that, it remains undisputed that BMI alone is an incomplete measure.

3. Symptoms and health effects

Obesity itself often does not cause acute pain — but the body frequently sends warning signs that many people do not connect with their weight:

  • Shortness of breath on exertion — e.g. when climbing stairs
  • Joint pain — especially the knees, hips, lower back
  • Tiredness during the day, reduced resilience
  • Increased sweating, heat intolerance
  • Heartburn — increased pressure in the abdomen can promote reflux
  • Back pain from the additional load on the spine
  • Skin problems: fungal infections in skin folds, acanthosis nigricans (can indicate insulin resistance)
  • Sleep disorders, low mood

4. Causes — why does obesity arise?

Obesity is usually NOT simply "eating too much, moving too little" The science shows a complex picture. Twin studies suggest that a substantial proportion of weight variation is genetically determined — estimates range from 40 to 70 %.²

Genetics

More than 300 gene loci influence hunger, satiety, metabolism and fat distribution. The satiety hormone leptin and the hunger hormone ghrelin can become out of balance in obesity (leptin resistance). Genetics does not determine whether someone becomes obese — but often how easily one gains weight and how difficult losing weight is.

Environment and lifestyle

  • Diet: often high in calories and low in nutrients, large portions, highly processed foods (fast food, ready meals, sugary drinks)
  • Lack of exercise: a sedentary job, the car instead of the bike, little everyday activity
  • Lack of sleep: persistently less than about 7 hours per night can increase the obesity risk
  • Stress: chronic stress promotes cortisol release → fat storage, emotional eating

Psychological factors

  • Emotional eating — eating as a coping strategy with stress, grief, boredom
  • Binge eating disorder — repeated binge episodes with a loss of control (a distinct mental health condition)
  • Depression and anxiety disorders — can be both a cause and a consequence of obesity

Medical factors

  • Hormonal disorders: e.g. hypothyroidism, PCOS, Cushing's syndrome
  • Medications: e.g. certain antidepressants, antipsychotics, cortisone, beta blockers, insulin, antiepileptics can promote weight gain
  • Gut microbiome: the composition of the gut bacteria can influence energy metabolism

Socioeconomic factors

According to RKI data, obesity is considerably more common in education groups with a lower socioeconomic status.¹ A healthy diet is often more expensive and more time-consuming. Social isolation and stigmatization can intensify the vicious circle.


5. Secondary diseases

Obesity is regarded as a risk factor for a multitude of accompanying and secondary diseases. As a rule: the higher the BMI and the longer the obesity persists, the higher the risk.

  • Type 2 diabetes — obesity is one of the most important risk factors²
  • Cardiovascular: high blood pressure, heart attack, stroke, heart failure
  • Fatty liver (MASLD) — common in people with obesity
  • Heartburn/GERD — among other things due to increased pressure in the abdomen
  • Sleep apnoea — pauses in breathing during sleep, daytime tiredness
  • Osteoarthritis — from overloading of the joints (e.g. the knees, hips)
  • Increased cancer risk for various tumour entities (e.g. bowel, kidney, oesophageal, uterine and postmenopausal breast cancer)
  • Depression, anxiety disorders, social isolation
  • Gallstones, gout, venous thromboses

6. Diagnosis

The diagnosis usually goes beyond the mere calculation of BMI:

  • Calculate the BMI and determine the obesity grade
  • Measure the waist circumference (to assess visceral fat)
  • Blood test: e.g. blood sugar, HbA1c, blood lipids, liver values, thyroid (TSH)
  • Measure blood pressure
  • Sleep apnoea screening (e.g. with snoring, daytime tiredness)
  • Record accompanying mental health conditions: depression, binge eating, other eating disorders
  • Medication history: are weight-promoting medications being taken?

More: Preparing for a doctor's appointment.


7. Step-wise treatment (S3 guideline 2024)

Treatment goal: approx. 5–10 % weight loss — not necessarily a normal weight This is often enough for marked improvements in the accompanying diseases. Depending on the starting situation, larger weight losses can also be sensible.²
Step 1 Lifestyle intervention — the basis for everyone

Diet

  • A moderate calorie reduction as part of an adjustment accompanied by a doctor or a nutritional therapist — no starving, no crash diets
  • Various evidence-based dietary patterns can be effective: e.g. the Mediterranean diet (well studied), low-carb, low-fat, intermittent fasting — the best dietary pattern is mostly the one that can be sustained in the long term²
  • Reduce highly processed foods (fast food, ready meals, sugary drinks) where possible
  • Formula diets can be an option as part of a medically supervised programme
  • Regular meals, mindful portion sizes

Exercise

  • Usually recommended: about 150–300 minutes per week of moderate physical activity (e.g. brisk walking, swimming, cycling)
  • A combination of endurance and strength training (building muscle can raise the basal metabolic rate)
  • Increase everyday activity: e.g. the stairs instead of the lift, on foot instead of the car, interrupt sitting time
  • Every bit of movement counts — even short sessions are usually better than none at all

Behavioural therapy

  • Keep a food diary — to become aware of eating behaviour
  • Identify triggers for emotional eating
  • Stress management (e.g. relaxation techniques, sleep hygiene)
  • Structured, multimodal programmes (e.g. the DMP obesity, a German disease management programme) often show better results than purely individual attempts²
Step 2 Medications — when lifestyle measures alone are not enough

The decision — which medication, in which situation and at which dose — is always made by the treating doctor. The newer generation of GLP-1 receptor agonists (colloquially "weight-loss injections") has changed the medication-based treatment of obesity in recent years.

How do GLP-1 receptor agonists work? Semaglutide and tirzepatide mimic the effect of the gut hormone GLP-1. They can slow down gastric emptying (a longer feeling of fullness) and act on the satiety centre in the brain. The effect: usually less hunger, faster satiety and — in some of those treated — a marked weight loss.
Use: usually injected subcutaneously once a week
Effectiveness (STEP-1 study): average weight loss ~14.9 % after 68 weeks vs. 2.4 % with placebo (n=1,961)
Side effects: often nausea, diarrhoea, constipation, vomiting — mostly at the start of therapy
Cost: ~300 EUR/month · Ozempic = a lower dose for type 2 diabetes
Tirzepatide (Mounjaro / Zepbound)
Drug class: a dual GLP-1/GIP receptor agonist — acts on two hormone receptors
Use: once a week subcutaneously
Effectiveness (SURMOUNT-1 study): at the highest dose an average of ~20 % weight loss after 72 weeks
Side effects: similar to semaglutide · Cost: ~400–500 EUR/month
Oral semaglutide (Rybelsus)
GLP-1 as a tablet — in Germany currently approved for the treatment of type 2 diabetes, not as an obesity medication. The weight loss is smaller in studies than with the injection.
Orlistat
Inhibits the absorption of fat in the gut. The weight effect in studies is usually smaller than with GLP-1 receptor agonists. Side effects: fatty stools, diarrhoea, flatulence. Available over the counter at a low dose.
In development (as of 2025/2026)
Orforglipron (Eli Lilly) — an oral GLP-1 tablet under review · Retatrutide — a triple agonist (GLP-1/GIP/glucagon) · CagriSema (Novo Nordisk) — a combination of semaglutide + an amylin analogue. Availability and approval can change at short notice.
Cost reimbursement: currently mostly only with diabetes With type 2 diabetes, GLP-1 receptor agonists (e.g. Ozempic, Mounjaro) are often covered by the statutory health insurers. With obesity without diabetes, Wegovy and Zepbound are currently usually not reimbursed by the statutory health insurance (in Germany GKV). When in doubt, ask your own health insurer.
Important: medications alone are usually not enough After stopping a GLP-1 therapy, the weight often partly comes back (among others, the STEP-4 study). In obesity, GLP-1 receptor agonists are mostly used as a long-term therapy for a chronic disease — this is decided individually by the doctor. More: Drug interactions, Stopping medications.
Step 3 Bariatric surgery (obesity surgery)

With a BMI ≥ 40 or a BMI ≥ 35 with relevant accompanying diseases (e.g. type 2 diabetes, high blood pressure, sleep apnoea), a bariatric operation can be considered when conservative measures have not worked sufficiently over a longer period. With a very high BMI (> 50), the operation can in individual cases also be an option earlier.²

ProcedureWeight lossParticular features
Sleeve gastrectomy (Schlauchmagen)~20–25 %A frequently used procedure. Usually not reversible.
Gastric bypass (Roux-en-Y)~25–35 %Regarded as one of the most effective procedures. Lifelong vitamin supplementation needed.
Gastric bandSmaller than the sleeveUsed less often today. Reversible in principle.
Gastric balloonTemporaryA bridging measure, not a permanent solution.
Table scrollable to the right

In severe obesity, bariatric surgery is one of the most effective long-term therapies. The procedural mortality is low in experienced centres.² Structured follow-up care (blood values, vitamins, nutritional counselling) is usually needed for life.


8. Obesity in children and adolescents

According to RKI data (the KiGGS study), about 6 % of children and adolescents in Germany have obesity, and about 15 % are overweight — the figures have been at a high level for years.

  • A relevant proportion of children with obesity remain obese into adulthood too
  • Early obesity can increase the risk of type 2 diabetes, high blood pressure and further secondary diseases later in life
  • Treatment: mostly a family-based lifestyle intervention (diet + exercise for the whole family)
  • Medications: semaglutide is approved in the EU from the age of 12 for obesity under certain conditions — always used by specialized doctors
  • Psychosocial strain (e.g. bullying, low self-esteem, depressive symptoms) should be addressed early
  • Bariatric operations are possible in adolescence in rare exceptional cases — exclusively in specialized centres

9. Mental health and stigmatization

Obesity goes far beyond a purely physical problem. Many of those affected experience discrimination — in the healthcare system, at work, in public. These experiences can impair self-esteem and promote mental health conditions.²

  • Binge eating disorder: repeated binge episodes with a loss of control — a distinct mental health condition that needs professional treatment
  • Emotional eating: eating as a coping strategy with stress, grief, loneliness
  • Depression and obesity can intensify each other
Psychotherapy is an important part of the treatment Cognitive behavioural therapy (CBT) is usually an important part of obesity treatment — not only for mental stability, but often also for long-term treatment success.

How brite helps you with obesity

brite brings structure to your therapy — from the weekly injection to the doctor's appointment.

  • Medication reminder — a weekly GLP-1 injection, blood-pressure-lowering medications, vitamins after a bariatric operation: brite reminds you reliably. Set up a reminder
  • Interaction check — a weight-loss injection plus blood-pressure-lowering medications, diabetes medications or thyroid hormones? Have it checked — for free. Check now
  • Digital medication plan — all your medications clearly laid out for your family doctor, nutritional medicine and surgery. Go to medication plan
Get started for free
brite App

FAQ: Common questions about obesity

Usually from a BMI of 30 kg/m². Example: at a height of 1.70 m, from about 87 kg. The waist circumference is also meaningful: over 88 cm (women) or 102 cm (men) indicates an increased cardiometabolic risk — even with a lower BMI.
Overweight is mostly defined with a BMI of 25–29.9 — an increased risk, but not necessarily a disease. Obesity is usually present from a BMI of 30 and has been officially recognized as a chronic disease in Germany since 2020. The Lancet Commission (2025) additionally proposes the distinction between clinical (with organ damage) and preclinical obesity (without organ damage).
In medicine, obesity is understood as a chronic disease — not as a weakness of will. A substantial part of weight variation is partly genetically determined. Hormones such as leptin and ghrelin influence hunger and satiety. Blaming those affected is neither professionally correct nor helpful.
In the STEP-1 study, an average weight loss of ~14.9 % after 68 weeks was described with semaglutide. With tirzepatide (SURMOUNT-1), up to around 20 % after 72 weeks. Individually, the response varies greatly — some of those treated respond markedly more poorly. Whether and how such a medication is used is decided by the treating doctor.
With type 2 diabetes: often yes (e.g. Ozempic, Mounjaro). With obesity without diabetes, Wegovy and Zepbound are currently usually not reimbursed by the statutory health insurance in Germany. The exact reimbursement situation can change — when in doubt, ask your own health insurer.
Often yes. Studies show that after stopping, a relevant part of the lost weight comes back (among others, the STEP-4 study). That is why medications are usually used as part of a long-term treatment — combined with lifestyle measures — and not as a "temporary cure".
Intermittent fasting (e.g. 16:8) can be an effective strategy — the evidence is roughly comparable with other calorie-reducing dietary patterns. What is decisive is mostly long-term sustainability. Anyone with pre-existing conditions should have the plan accompanied by a doctor.
Usually from a BMI ≥ 40 — or from a BMI ≥ 35 with relevant accompanying diseases (e.g. type 2 diabetes, high blood pressure, sleep apnoea), when conservative measures have not worked sufficiently over a longer period. The exact indication is set individually at a specialized centre.²

12. Related topics

Sources

  1. RKI: Übergewicht und Adipositas bei Erwachsenen — GEDA 2019/2020-EHIS, Journal of Health Monitoring 3/2022. rki.de
  2. S3-Leitlinie Prävention und Therapie der Adipositas, AWMF Reg-Nr. 050-001 (2024). awmf.org
  3. Rubino F. et al.: Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol, Januar 2025. thelancet.com
  4. Wilding J.P.H. et al.: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021; 384:989–1002. nejm.org
  5. Jastreboff A.M. et al.: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022; 387:205–216. nejm.org
  6. Rubino D. et al.: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021; 325(14):1414–1425. jamanetwork.com
  7. RKI: Adipositas und Übergewicht — KiGGS-Studie. rki.de
  8. gesundheitsinformation.de (IQWiG): Starkes Übergewicht (Adipositas). gesundheitsinformation.de
  9. WHO: Obesity and Overweight — Fact Sheet. who.int
Medical disclaimer: This article is for general information and does not replace medical advice, diagnosis or treatment. Doses, the choice of medication and the indication (e.g. for a bariatric operation) are always determined individually by the treating doctor. Last updated: April 2026.